You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

SARS-CoV-2, Vaccines, Mix and Match Trial

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Covid19 Trial in Maputo (BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell), Ad26.COV2.S (Recombinant,

Recruiting
  • Covid19
  • BBIBP-CorV - Inactivated SARS-CoV-2 vaccine (Vero cell)
  • +2 more
  • Maputo, Mozambique
    Centro de Investigação e Treino em Saúde da Polana Caniço - Inst
Mar 31, 2022

COVID-19 Trial in Canada (mRNA-1273 SARS-CoV-2 vaccine, BNT162b2, ChAdOx1-S [recombinant])

Recruiting
  • COVID-19
  • mRNA-1273 SARS-CoV-2 vaccine
  • +4 more
  • Edmonton, Alberta, Canada
  • +7 more
Mar 7, 2022

COVID-19 Trial (NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg))

Not yet recruiting
  • COVID-19
  • NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
  • Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
  • (no location specified)
Aug 4, 2023

Sars-Covid-19 Vaccines in Haematological Patients: Prospective

Completed
  • Hematologic Diseases
  • IgG antibodies to Sars-Cov-2
  • QuantiFERON SARS-CoV-2 test
  • Monza, Lombardia, Italy
    San Gerardo Hospital
Jan 23, 2023

SARS-CoV-2 Infection, Varicella, Measles Trial in Shanghai (Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine,

Not yet recruiting
  • SARS-CoV-2 Infection
  • +4 more
  • Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Municipal Center for Disease Control and Prevention
Jul 17, 2023

Immunogenicity, Safety Trial (Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2;)

Not yet recruiting
  • Immunogenicity
  • Safety
  • Phase II:SWIM816;SARS-Cov-2;
  • +3 more
  • (no location specified)
Jun 18, 2023

COVID-19 Trial in Jakarta (ABO1009-DP, ABO-CoV.617.2, Placebo)

Recruiting
  • COVID-19
  • ABO1009-DP
  • +2 more
  • Jakarta, Indonesia
  • +1 more
Jul 25, 2022

Humoral and Cellular Immunity Against SARS-COV-2 Vaccine in

Active, not recruiting
  • SARS-CoV-2 RNA Vaccines
  • HIV Infection
  • SARS-CoV-2 Vaccine
  • Sevilla, Spain
    Virgen del Rocio University Hospital
Dec 1, 2022

Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster

Terminated
  • Anti-SARS-CoV-2 Antibody Response
  • blood and saliva samples will be taken
  • Graz, Austria
    Medizinische Universität Graz, Klinische Abteilung für Rheumatol
Jan 9, 2023

Multiple Sclerosis Trial in Germany (Ofatumumab)

Active, not recruiting
  • Multiple Sclerosis
  • Berlin, Germany
  • +5 more
Jan 13, 2023

COVID-19, SARS CoV 2 Infection Trial in Australia (NVX-CoV2515, NVX-Cov2373, NVX-CoV2373 + NVX-CoV2515)

Active, not recruiting
  • COVID-19
  • SARS CoV 2 Infection
  • Bruce, Australian Capital Territory, Australia
  • +18 more
Nov 23, 2022

Against Sars-Cov2 Virus in Received EU-approved COVID-19

Completed
  • SARS-CoV2 Infection
  • Vaccine Reaction
  • Approved vaccines against Sars-Cov2
  • Patras, Greece
    University Hospital of Patras
Jun 2, 2022

Multiple Myeloma Trial (Patient Reported Outcomes)

Not yet recruiting
  • Multiple Myeloma
  • Patient Reported Outcomes
  • (no location specified)
Apr 24, 2023

SARS-CoV-2 Infection Among Healthcare Workers

Recruiting
  • COVID-19
  • inactivated COVID-19 vaccines; orally aerosolized Ad5-nCoV
  • Nanjing, Jiangsu, China
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Jan 10, 2023

SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in

Recruiting
  • COVID-19
    • Baltimore, Maryland
    • +1 more
    Feb 2, 2023

    SARS-CoV-2 Trial in Melbourne (Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59),

    Recruiting
    • SARS-CoV-2
    • Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)
    • +2 more
    • Melbourne, Victoria, Australia
    • +1 more
    Apr 25, 2022

    Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

    Recruiting
    • SARS-CoV-2
    • SPIKEVAX
    • New York, New York
      Aetion, Inc
    Nov 8, 2023

    COVID-19 Pandemic, COVID-19 Vaccines Trial in Surabaya (Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg,

    Recruiting
    • COVID-19 Pandemic
    • COVID-19 Vaccines
    • Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg
    • CoronaVac Biofarma COVID-1 9 Vaccine 3 µg
    • Surabaya, East Java, Indonesia
      Dr. Soetomo General Hospital
    Jun 21, 2023

    COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2)

    Completed
    • SARS CoV 2 Infection
      • Xi'an, Shaanxi, China
        First Affiliated Hospital of Xian JiaotongUniversity
      Feb 16, 2022

      COVID-19, Vaccines Trial in Santiago (CoronaVac®, Omicron Vaccine, Trivalent Vaccine)

      Recruiting
      • COVID-19
      • Vaccines
      • CoronaVac®
      • +2 more
      • Santiago, Metropolitana, Chile
      • +2 more
      Jan 12, 2023

      COVID-19, SARS-CoV-2 Infection Trial (SCTV01E-2, SCTV01E)

      Not yet recruiting
      • COVID-19
      • SARS-CoV-2 Infection
      • SCTV01E-2
      • SCTV01E
      • (no location specified)
      Jul 4, 2023

      Coadministration of Influenza Vaccination With Booster Dose of

      Completed
      • Co-administration of COVID-19 and Influenza Vaccines
      • COMIRNATY
      • Roma, RM, Italy
        Fondazione Policlinico Gemelli
      Mar 10, 2023

      Transverse Myelitis Related to SARS-CoV-2 Vaccines

      Completed
      • Vaccine Adverse Reaction
      • SARS-CoV-2 vaccines
      • Caen, Basse Normandie, France
        Alexandre Joachim
      Jan 3, 2022

      SARS-CoV Infection Trial in Denmark (COMIRNATY - BioNTech Manufacturing GmbH, COVID-19 Vaccine Moderna dispersion for injection

      Recruiting
      • SARS-CoV Infection
      • COMIRNATY - BioNTech Manufacturing GmbH
      • +2 more
      • Aarhus, Aarhus N, Denmark
      • +4 more
      Apr 11, 2022

      COVID-19 Vaccines Trial in Hannover (MVA-SARS-2-ST)

      Recruiting
      • COVID-19 Vaccines
      • MVA-SARS-2-ST
      • Hannover, Germany
        Hannover Medical School ZKS - Early Clinical Trial Unit at CRC H
      Sep 6, 2022